GlassScriptPhysician profile
Gary H Miller
NPI 1386606952
$5,212.49
in general payments reported to CMS, 2019-2025
19 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $141 · 2021: $172 · 2022: $799 · 2023: $850 · 2024: $808 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,352 · Food and Beverage: $1,079 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,352.14 |
| Food and Beverage | $1,079.31 |
| Education | $222.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $3,135.47 | 2022-2025 | (8269) Dreamstation Cpap, Dreamstation Cpap |
| Astrazeneca Pharmaceuticals LP | $421.75 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Insmed, INC. | $262.05 | 2019-2025 | Brinsupri, Arikayce |
| Glaxosmithkline, LLC. | $212.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $180.69 | 2020-2025 | |
| Zoll Respicardia, INC. | $172.26 | 2021 | |
| Amgen INC. | $154.32 | 2019-2025 | Tezspire, Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $133.33 | 2025 | Opsumit, Uptravi |
| Genzyme Corporation | $116.69 | 2019-2025 | |
| Verona Pharma, INC. | $113.81 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $78.46 | 2025 | Yupelri |
| Novo Nordisk INC | $50.12 | 2024-2025 | Ozempic, Wegovy |
| Jazz Pharmaceuticals INC. | $36.16 | 2019 | |
| Exact Sciences Corporation | $33.43 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $32.89 | 2025 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.67 | 2019 | |
| Genentech USA, INC. | $23.40 | 2019 | |
| Pfizer INC. | $16.66 | 2025 | |
| Medicure Pharma INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.